ImpediMed Stock

ImpediMed EBIT

The EBIT of ImpediMed (IPD.AX) as of Jun 22, 2026 is -23.01 T AUD.In the previous year, EBIT was -21.22 T AUD — a change of 8.41% (lower).

EBIT

-23.01 TAUD

YoY

8.41%

Last updated:

In 2026, ImpediMed's EBIT was -23.01 T AUD, a 8.41% increase from the -21.22 T AUD EBIT recorded in the previous year.

The ImpediMed EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (undefined AUD)
Date
EBIT (undefined AUD)
Jan 1, 2006
0 base
Jan 1, 2007
0 base
Jan 1, 2008
0 base
Jan 1, 2009
0 base
Jan 1, 2010
0 base
Jan 1, 2011
0 base
Jan 1, 2012
0 base
Jan 1, 2013
0 base
Jan 1, 2014
0 base
Jan 1, 2015
0 base
Jan 1, 2016
0 base
Jan 1, 2017
0 base
Jan 1, 2018
0 base
Jan 1, 2019
0 base
Jan 1, 2020
0 base
YEAREBIT (undefined AUD)
2028 est -
2027 est -
2026 est -
2025 -
2024 -
2023 -
2022 -
2021 -
2020 -
2019 -
2018 -
2017 -
2016 -
2015 -
2014 -
2013 -
2012 -
2011 -
2010 -
2009 -
2008 -
2007 -
2006 -
Access this data via the Eulerpool API

ImpediMed Revenue

ImpediMed Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2006
1.08 M AUD
-4.94 M AUD
-7.58 M AUD
Jan 1, 2007
1.94 M AUD
-7 M AUD
-10.13 M AUD
Jan 1, 2008
2.99 M AUD
-8.06 M AUD
-9.76 M AUD
Jan 1, 2009
3.27 M AUD
-13.68 M AUD
-14.03 M AUD
Jan 1, 2010
3.81 M AUD
-11.34 M AUD
-11.4 M AUD
Jan 1, 2011
4.17 M AUD
-11.91 M AUD
-14.82 M AUD
Jan 1, 2012
3.18 M AUD
-12.71 M AUD
-12.34 M AUD
Jan 1, 2013
2.93 M AUD
-8.42 M AUD
-8.46 M AUD
Jan 1, 2014
3.58 M AUD
-7.95 M AUD
-7.94 M AUD
Jan 1, 2015
4.93 M AUD
-14.8 M AUD
-14.8 M AUD
Jan 1, 2016
5.95 M AUD
-23.66 M AUD
-25.98 M AUD
Jan 1, 2017
6.13 M AUD
-27.5 M AUD
-27.57 M AUD
Jan 1, 2018
3.32 M AUD
-27.65 M AUD
-27.37 M AUD
Jan 1, 2019
4.16 M AUD
-24.31 M AUD
-24.12 M AUD
Jan 1, 2020
5.74 M AUD
-22.9 M AUD
-21.38 M AUD

ImpediMed Margins

ImpediMed stock margins

The ImpediMed margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ImpediMed. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ImpediMed.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2006
50.93 %
-457.41 %
-701.85 %
Jan 1, 2007
67.53 %
-360.82 %
-522.16 %
Jan 1, 2008
76.92 %
-269.57 %
-326.42 %
Jan 1, 2009
55.35 %
-418.35 %
-429.05 %
Jan 1, 2010
57.74 %
-297.64 %
-299.21 %
Jan 1, 2011
60.43 %
-285.61 %
-355.4 %
Jan 1, 2012
60.38 %
-399.69 %
-388.05 %
Jan 1, 2013
59.73 %
-287.37 %
-288.74 %
Jan 1, 2014
59.78 %
-222.07 %
-221.79 %
Jan 1, 2015
73.13 %
-300.45 %
-300.32 %
Jan 1, 2016
73.38 %
-397.85 %
-436.86 %
Jan 1, 2017
75.72 %
-448.44 %
-449.55 %
Jan 1, 2018
70.58 %
-833.36 %
-824.95 %
Jan 1, 2019
69.87 %
-584.94 %
-580.44 %
Jan 1, 2020
70.77 %
-398.95 %
-372.36 %

ImpediMed Stock analysis

What does ImpediMed do? ImpediMed Ltd is an Australian company specializing in medical devices and technologies. They were founded in 1999 and have their headquarters in Brisbane, Australia. The company is a leading provider of bioimpedance measurement devices for the diagnosis, monitoring, and treatment of lymphatic, cardiac, and other medical conditions. They have a wide range of products used in various medical fields, including oncology, lymphology, and cardiology. Their main business model is based on the development and marketing of their bioimpedance measurement devices. They also provide training and support for medical personnel to optimize the use of their devices. ImpediMed specializes in the diagnosis and treatment of lymphedema in the oncology sector, particularly using their highly precise L-Dex® device. They also analyze body composition in the cardiology sector to determine the risk of heart diseases and develop personalized treatment approaches. In recent years, ImpediMed has expanded into the European market, particularly in lymphedema diagnosis and treatment. Overall, ImpediMed Ltd is an innovative company that focuses on medical devices and technologies for the diagnosis and monitoring of cardiac and lymphatic diseases. They provide important diagnostic capabilities to medical professionals and continue to focus on growth and expansion. ImpediMed is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing ImpediMed's EBIT

ImpediMed's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of ImpediMed's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

ImpediMed's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in ImpediMed’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about ImpediMed stock

EBIT of ImpediMed amounted to -21.22 T AUD -23.01 T

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — ImpediMed

All Key Metrics — ImpediMed